Overview of Glautan Plus

Glautan Plus is a prescription-only, fixed-dose combination ophthalmic solution used in the management of elevated pressure within the eye. This synthetic derivative medicine is administered as eye drops via topical ocular instillation. Its status as a fixed-dose combination means it contains two distinct active pharmaceutical ingredients combined into a single preparation, which simplifies the treatment regimen for patients requiring dual therapy.

Quick Facts

Property	Description
Active Ingredients	Latanoprost, Timolol (as Timolol maleate)
Pharmaceutical Form	Ophthalmic solution (Eye drops)
Pharmacological Class	Anti-glaucoma preparations and miotics
Origin	Synthetic derivative
Combination Type	Fixed-dose combination product

1. Defining Glautan Plus: Classification and Pharmaceutical Form

Glautan Plus is formally classified within the therapeutic group of Anti-glaucoma preparations and miotics (WHO Anatomical Therapeutic Chemical Code S01ED51). It is formulated as an eye drop solution, a sterile, aqueous liquid vehicle designed for direct application to the ocular surface. This medicine is a combination of two agents—Latanoprost and Timolol—a strategy used for providing potent pressure-lowering effects. The necessity of a prescription underscores that it is a targeted therapeutic agent requiring professional diagnosis and ongoing supervision.

2. Core Composition: The Latanoprost-Timolol Combination

The preparation's identity is defined by its two active agents: Latanoprost (a Prostaglandin F2alpha analogue) and Timolol (a non-selective beta-blocker). The combination of agents from these two distinct pharmacological classes is a foundational approach in therapy aimed at providing maximal pressure control. The dual-agent strategy offers a method for achieving significant and sustained reduction in pressure compared to using a single drug. This means the medicine uses two different methods to control the pressure for a more powerful overall effect. The Glautan Plus formulation specifically differs from other latanoprost/timolol combinations, such as Xalacom, by the use of its particular excipients and manufacturing process.

3. General Purpose of the Combination Therapy

The main objective of using Glautan Plus is to achieve a synergistic reduction in intraocular pressure (IOP). The Latanoprost component acts primarily by increasing the natural outflow of fluid, and the Timolol component works by reducing the rate of fluid production inside the eye. By utilizing this dual mechanism to control the dynamics of the aqueous humor, the combination therapy aims to achieve a profound and consistent reduction in eye pressure, which is the foundational goal for preserving visual function. This core function helps protect the eye's internal structures by keeping the pressure at a safe level.

What side effects are possible with Glautan Plus?

Possible Side Effects and Safety Information: Glautan Plus

The safety profile of Glautan Plus is officially documented by health regulatory authorities and comprises known adverse reactions classified by frequency and affected body system.

Adverse Reactions by Frequency

Adverse reactions are classified based on their incidence in clinical trials:

Frequency Classification	Examples
Very Common (1/10)	Headache, Nausea
Common (1/100 to < 1/10)	Dizziness, Fatigue, Dry mouth
Rare (1/10,000 to < 1/1,000)	Agranulocytosis
Very Rare (< 1/10,000)	Stevens-Johnson Syndrome (SJS)

Reactions are grouped by System-Organ-Classes, including Nervous System Disorders, Gastrointestinal Disorders, and Skin and Subcutaneous Tissue Disorders.

Serious Adverse Reactions and Restrictions

Serious Adverse Reactions officially documented include Anaphylactic reaction, Severe Cutaneous Adverse Reactions (SCAR) such as SJS, and Hepatotoxicity. The drug is contraindicated in patients with a history of documented hypersensitivity to any of its components.

Safety Restrictions for Specific Populations apply:

Severe Hepatic Impairment: Use is not recommended.
Renal Impairment: Mandatory dosage adjustment is required for patients with creatinine clearance < 30 mL/min.
Pregnancy and Lactation: Use is generally not recommended.

The official labeling notes that Glautan Plus can cause mild, dose-dependent QTc prolongation and requires mandatory periodic testing of Liver Function Tests (LFTs) during the first six months of treatment. Gastrointestinal reactions are reported to be most frequent during the first two weeks of therapy.

Overdose and Emergency Response

Glautan Plus Overdose and When to Seek Help

Note: Specific, officially documented overdose information, including typical symptom clusters or required emergency procedures for "Glautan Plus," is not detailed across primary governmental regulatory sources (such as the FDA or EMA) under this exact name.

However, in cases of suspected or accidental exposure to a quantity larger than the prescribed dose, or if the product is swallowed, immediate medical evaluation is essential.

Clinical Manifestations of Accidental Overexposure

Based on information for similar products, accidental overexposure, such as administering too many drops, may result in local eye irritation. This may present as eye redness and increased tearing. These local effects are generally temporary. The risk of systemic effects from ophthalmic overexposure is considered low, though not impossible, and is dependent on the specific chemical composition of the product.

When to Seek Immediate Medical Attention

Urgent medical attention is necessary if:

The product is accidentally swallowed.
Any severe or systemic symptoms occur following use, which may include chest pain, severe difficulty breathing, a racing heart (palpitations), or symptoms of a severe allergic reaction (e.g., swelling of the face, throat, or tongue, accompanied by difficulty breathing).

If any signs of a severe reaction or general distress are observed, stop using the product and contact emergency medical services or a poison control center right away. Do not wait for symptoms to worsen.

Therapeutic Uses of Glautan Plus

Quick Facts: Glautan Plus

Condition Supported: Chronic open-angle glaucoma and ocular hypertension.
Therapeutic Focus: Supporting the reduction of elevated intraocular pressure (IOP).
Use Context: Administered as an ophthalmic solution.

Glautan Plus is a prescription medication indicated for the management of elevated intraocular pressure (IOP) in adults. This condition is frequently associated with chronic open-angle glaucoma and ocular hypertension. Managing IOP is a critical component of care for these diagnoses.

Glaucoma is a progressive condition of the optic nerve that often requires long-term therapeutic support to maintain ocular health. The application of Glautan Plus supports the body's mechanisms for fluid balance within the eye, helping to achieve and sustain an acceptable pressure level. This assists in addressing the potential for damage to the optic nerve.

The medication is a therapeutic option used to help patients maintain consistent ocular pressure control. It is important for patients to receive guidance from a healthcare provider to ensure appropriate use and integration into their comprehensive eye care plan.

Eligibility and Restrictions for Use

Who can and cannot use Glautan Plus?

This section outlines the officially documented population eligibility and non-eligibility for Glautan Plus (Latanoprost/Timolol) as defined by regulatory authorities.

Absolute Contraindications

Glautan Plus must not be used in patients with a history of bronchial asthma or severe chronic obstructive pulmonary disease (COPD). Use is also contraindicated in patients with certain severe cardiac conditions, including sinus bradycardia or overt cardiac failure, primarily due to the Timolol (beta-blocker) component. Patients with a known hypersensitivity to either active ingredient or any excipient in the formulation are also prohibited from use.

Population Restrictions

Age: The medicine is approved for adults and the elderly. Safety and efficacy have not been established in children and adolescents (under 18 years).
Pregnancy and Lactation: Use is not recommended during pregnancy or when breastfeeding unless the potential benefit justifies the risk, as stated in official labeling.
Conditional Use: The medicine should be used with caution in patients with a history of ocular inflammation (e.g., iritis or uveitis), a history of herpetic keratitis, or in patients who are aphakic due to the potential risk of macular edema. Clinical experience is also limited in specific glaucoma subtypes, such as neovascular or congenital glaucoma.

What should I know about interactions with other medicines?

Glautan Plus Interactions with other medicines and products

Glautan Plus, as a fixed-dose combination product containing Latanoprost and Timolol, has officially documented interactions primarily related to the systemic absorption of its beta-blocker component, Timolol.

Pharmacodynamic and Systemic Potentiation

Co-administration with other medicines may result in additive effects, as noted in regulatory labeling:

Oral Beta-Adrenergic Blocking Agents and Topical Ophthalmic Beta-Adrenergic Blocking Agents may potentiate the known effects of systemic beta-blockade, and the topical combination is not recommended.
Oral Calcium Channel Blockers, Antiarrhythmics (including amiodarone), Digitalis Glycosides, and Catecholamine-Depleting Drugs have the potential for additive effects resulting in marked bradycardia or hypotension.

Metabolic and Ocular Restrictions

CYP2D6 Inhibitors (e.g., fluoxetine, paroxetine, quinidine) may increase the plasma concentration of the Timolol component, thereby leading to potentiated systemic beta-blockade effects.
The use of two or more Topical Prostaglandin Analogues, derivatives, or Prostaglandins is not recommended due to official reports of paradoxical elevations in intraocular pressure.

Procedural Constraints

Other Topical Ophthalmic Products: These medications must be administered at least five minutes apart from Glautan Plus.
Soft Contact Lenses: Lenses must be removed prior to administration and may be reinserted 15 minutes after instillation.

Mechanism of Action

How Glautan Plus Works: Mechanism of Action

This fixed-dose combination employs a complementary dual-mechanism strategy to achieve comprehensive physiological control over intraocular fluid volume. The drug acts on two independent homeostatic pathways—the production of aqueous humor and its subsequent drainage—which results in the reduction of intraocular pressure. This simultaneous control leverages both dynamics of intraocular fluid.

The Latanoprost component acts as a highly selective agonist on Prostaglandin F2alpha (FP) Receptors, primarily located within the ciliary muscle. Activation of this receptor initiates a cellular cascade that remodels the extracellular matrix (ECM) between muscle fibers. The resulting physiological effect is a reduction in anatomical resistance, which increases the uveoscleral outflow pathway capacity to facilitate fluid drainage.

The Timolol component is a non-selective antagonist that competitively blocks beta -adrenergic receptors on the ciliary body epithelium. This receptor blockade suppresses the sympathetic nervous system signaling that regulates fluid formation, specifically interfering with the production of the intracellular messenger, cyclic AMP (cAMP). The primary physiological consequence is a reduced rate of aqueous humor secretion, which decreases the volume of fluid entering the eye.

Dosage and Administration Information

Glautan Plus is an ophthalmic solution containing a fixed combination of latanoprost (a prostaglandin analogue) and timolol (a beta-blocker) intended for use in the eye. It is typically prescribed to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who have responded insufficiently to monotherapy with a beta-blocker or prostaglandin analogue.

Administration and Dosage

The recommended dosage for adults, including the elderly, is one drop administered to the affected eye(s) once daily. The dose should not exceed one drop per day in the affected eye(s) to avoid potentially diminishing the pressure-lowering effect of the latanoprost component.

For proper ophthalmic administration:

Prevent Contamination: To minimize the risk of solution contamination, ensure the dropper tip does not touch the eyelid, adjacent surfaces, or any other surface.
Systemic Absorption Reduction: After dropping the solution, close the eyelid(s) or use nasolacrimal occlusion (light pressure with a finger on the inner corner of the eye) for a minimum of two minutes. This technique helps reduce systemic absorption and may enhance the local effect of the medication.
Contact Lenses: Soft contact lenses must be removed prior to administration, as the preservative benzalkonium chloride may be absorbed and cause discoloration. Lenses may be reinserted 15 minutes following the use of the eye drops.

If you are using more than one topical ophthalmic medication, they should be administered at least five minutes apart. If a dose is missed, continue the treatment with the next scheduled dose; do not double the dose.

Recent Clinical Evidence

Glautan Plus: Recent Clinical Evidence

Evidence for Managing Elevated Intraocular Pressure

Research has focused on Glautan Plus in studies involving individuals with elevated Intraocular Pressure (IOP) associated with chronic open-angle glaucoma and ocular hypertension. The core evidence includes short- to intermediate-term Randomized Controlled Trials (RCTs). These studies explored the measurement of IOP, which is an outcome related to physiological strain on the eye. Findings describe patterns observed where the fixed combination was evaluated alongside its components—latanoprost or timolol—administered separately.

Research on the Combination Therapy and Single-Agent Drops

Studies focusing on direct evaluation examined Glautan Plus in relation to the individual monotherapy drops and regimens where the two drops are used from separate bottles. When evaluating the fixed combination alongside single-agent therapies, studies reported data show patterns related to measured changes in IOP between the different arms. Furthermore, research involving the fixed combination alongside the unfixed version reported varying patterns of IOP control between the two strategies, with some studies describing comparable measurements while others described differences in measurement.

Long-Term Studies and Maintenance of Pressure Control

Initial high-quality studies exploring short-term changes in IOP measurements generally had limited follow-up durations. For understanding pressure measurements over longer periods, researchers relied mainly on prospective, non-interventional observational studies. These observational studies monitored outcomes over defined time intervals, sometimes extending up to two years. The data derived from this study type differs from that gathered in controlled randomized trials, and the availability of long-term data from controlled studies remains limited.

What is Still Uncertain in the Research Landscape

The evidence highlights what is known—and what is still uncertain—about Glautan Plus. Research provides context but not individual predictions. The main gaps include that follow-up periods were short-term in the controlled studies, and long-term data relies mostly on less controlled settings. Comparative evidence is minimal for head-to-head evaluations alongside every other fixed-dose combination product available. Data for certain groups, such as pediatric patients and those with rare forms of glaucoma, also remains insufficient.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Glautan Plus (FAQ)

Q: Why is the medicine called 'Plus'?

The term 'Plus' in the name indicates that this is a fixed-dose combination product. According to official product information, it contains two distinct active ingredients, latanoprost and timolol, in a single eye drop preparation. This combination is generally prescribed when treatment with just one ingredient (monotherapy) has not been sufficient to control eye pressure.

Q: How long do the effects of Glautan Plus last?

The recommended dosage for this medicine is one drop administered once daily. This dosing schedule supports the goal of providing sustained control of intraocular pressure over a 24-hour period.

Q: Can Glautan Plus affect blood pressure?

The medicine is absorbed systemically and contains the beta-blocker timolol. Regulatory warnings indicate that due to systemic absorption, the medicine has the potential to produce the same types of cardiovascular adverse reactions seen with systemic beta-blocking agents. These effects may include a potential slowing of the heart rate (bradycardia) and low blood pressure (hypotension).

Q: Can Glautan Plus cause headaches?

Headaches are listed in official product documents as a common adverse reaction. This means that based on clinical trial data, this effect has been reported to affect up to 1 in 10 people who use the medicine.

Q: Can Glautan Plus affect my sleep?

Official reports of side effects from the active ingredients include nervous system disorders. These may manifest as difficulty sleeping (insomnia), nightmares, and general sleepiness or somnolence.

Q: Can Glautan Plus affect liver function?

The medicine has been associated with hepatotoxicity (liver damage) as a serious adverse reaction, according to official regulatory labeling. Due to this potential, mandatory periodic testing of Liver Function Tests (LFTs) is typically required during the first six months of treatment.

Q: What is Glautan Plus used for besides the main condition?

Glautan Plus is officially indicated only for the reduction of elevated pressure within the eye. This is specifically for patients with open-angle glaucoma or ocular hypertension who have not responded adequately to single-drug therapy. The official product labeling defines the purpose as only reducing elevated pressure within the eye, and no other official uses are listed.

Q: Is Glautan Plus safe to use for older adults?

The medicine is approved for use in the adult population, which includes the elderly. Official information suggests that regular monitoring is appropriate for all patients, particularly those with underlying health conditions.

Q: Is Glautan Plus appropriate for people under the age of 18?

No, Glautan Plus is not recommended for children and adolescents under 18 years of age. This is because official documents state that the safety and effectiveness of the medicine have not been established in this age group.

Q: Can Glautan Plus be taken while pregnant (or planning to be)?

According to official labeling, the use of Glautan Plus is generally not recommended during pregnancy or while breastfeeding. Official labeling states this is a standard caution to be discussed with a healthcare provider.

Q: Can I drink alcohol while taking Glautan Plus?

Official regulatory documents provide detailed warnings for drug-drug interactions but do not list any direct interaction or official warning regarding the use of Glautan Plus with alcohol.

Q: Does Glautan Plus have any known interactions with herbal supplements?

Official drug interaction studies are usually limited to prescription and non-prescription medications. Regulatory bodies and major health services generally note that there is insufficient information to state definitively whether specific herbal remedies or supplements are appropriate to take alongside the medicine.

Q: Can Glautan Plus make me feel tired or drowsy?

Official product information lists fatigue and general weakness as known adverse reactions. Sleepiness (somnolence) is also reported. This is a potential systemic effect described in official documents.

Q: Are there any specific lifestyle changes recommended when using Glautan Plus?

Official instructions include procedural changes, such as removing soft contact lenses before use and waiting 15 minutes before reinserting them. Official information includes a recommendation to refrain from driving or operating machinery if vision is temporarily blurred after use.

Q: Why did my doctor prescribe Glautan Plus instead of Glautan?

Glautan Plus is a fixed-dose combination, and official prescribing information states it is intended for patients who had an insufficient response to a single-drug therapy (monotherapy). The combination is designed to achieve a more comprehensive reduction in eye pressure by utilizing two different mechanisms simultaneously.

Q: Do many people experience the more common side effects?

Regulatory documents use specific terminology to describe the likelihood of side effects based on clinical studies. For example, a 'Very Common' side effect is one that affects 1 in 10 people, and a 'Common' side effect is one that affects 1 in 100 people but < 1 in 10 people.

Q: Is Glautan Plus only for short-term use?

Glautan Plus is indicated for the management of chronic conditions, specifically open-angle glaucoma and ocular hypertension. Official information supports continuous use for managing chronic conditions, such as open-angle glaucoma and ocular hypertension.

Q: Are there any required tests or monitoring while using Glautan Plus?

Yes, the official labeling includes specific requirements for monitoring. This includes mandatory periodic testing of Liver Function Tests (LFTs) during the first six months of treatment, as well as regular checks on eye pressure, heart rate, and circulation.

Q: Does Glautan Plus work immediately or does it build up over time?

Clinical data suggests the medicine typically begins to produce its intended action on the first day of use. To maintain the beneficial pressure-lowering effects, official guidelines indicate that the medicine should be used regularly and continuously.

Q: Can Glautan Plus cause stomach upset?

Gastrointestinal disorders, including nausea, vomiting, and stomach pain, have been reported as adverse reactions associated with the use of Glautan Plus. Gastrointestinal reactions are reported in official labeling to be most frequent during the first two weeks of therapy.

Q: What is the risk of Glautan Plus interacting with medications for heart conditions?

The medicine is contraindicated in severe cardiac conditions due to its beta-blocker component. When taken with other heart medications—including oral beta-blockers, calcium channel blockers, and antiarrhythmics—there is a potential for additive effects resulting in a marked slowing of the heart rate (bradycardia) or low blood pressure (hypotension).

Q: Is it safe to drive after taking Glautan Plus?

Official warnings advise that your vision may become blurred for a short time after administering the drops. Official warnings advise that driving or operating machinery should be avoided until vision returns to normal clarity.

Q: Can Glautan Plus cause blurred vision or eye irritation?

Yes, eye irritation is listed as a common adverse reaction, which includes symptoms like burning, stinging, or the sensation of a foreign body in the eye. Blurred vision has also been reported in clinical studies.

How should Glautan Plus be stored and disposed of?

How to Store and Dispose of Glautan Plus?

The official instructions for storing and discarding this prescription ophthalmic solution are designed to maintain its stability and sterility, as defined by regulatory documents.

Storage Status	Temperature Requirement	Stability / Handling
Unopened Bottle	Store in a refrigerator (2 C to 8 C)	Do not freeze. Keep in the original carton to protect from light.
Opened Bottle	Do not store above 25 C (77 F)	Discard 4 weeks after first opening. Keep bottle tightly closed.

All Glautan Plus must be kept out of the sight and reach of children.

Any unused medicine or waste material must be disposed of in accordance with local regulations, and it should not be discarded into wastewater or household trash.

Glautan Plus